Hoje saem os resultados de várias big caps nos Estados Unidos .
Sabendo-so como se sabe que às vezes o resultado de uma só destas gigantes trás mexidas e indica direcções ao mundo inteiro , não é de admirar que os Mercados aguardem com alguma expectativa o que se vái passar .
Conforme os resultados e perspectivas futuras que sairem hoje , saberemos como vão reagir os Mercados nos próximos dias . Ou pelo menos , ajudará a traçar um rumo .
Chip giant Intel is set to announce third-quarter earnings on Tuesday afternoon. Analysts polled by Thomson First Call expect the company to post a profit of 18 cents per share on sales of $8.62 billion. In the year-ago quarter, Intel reported earnings of 32 cents per share on sales of $9.96 billion. Prudential Equity Group remained "underweight" on the stock, according to an Oct. 11 report. "For the September quarter, we think that unit shipments for Intel came in at above-seasonal levels, but that pricing and mix were a challenge," it said. "Longer term, we remain concerned about capacity for the industry in general, and about margins and market share for Intel specifically."
Health care giant Johnson & Johnson (nyse: JNJ - news - people ) will release results for the third quarter on Tuesday prior to the start of trading. J&J is expected to announce profit growth of just 7% from the year-ago quarter, or 93 cents per share. Sales are expected to rise 6%, to $13.08 billion, according to analysts. Uncertainty in the medical device market and patent expirations for key drugs has weighed on the stock in recent months. Credit Suisse reiterated an "underperform" rating on J&J shares Monday and said investors are likely to focus on the status of Paliperidone, an experimental schizophrenia treatment delayed by federal health regulators late last month. "Paliperidone's final approval timing is critical, as J&J needs to convert its Risperdal franchise to Paliperidone before exclusivity on Risperdal is lost in June 2008."
Yahoo! (nasdaq: YHOO - news - people ) will report results for the fiscal third quarter on Tuesday after the closing bell. Analysts predict the Internet services company to log earnings of 11 cents per share on revenue of $1.14 billion, compared with year-ago earnings of 16 cents per share on revenue of $932 million. Earlier today, Lehman Brothers cut earnings estimates to reflect "more realistic expectations" for the company's near-term outlook. "We believe Yahoo! is now a show-me stock, and the market is likely to give Yahoo! little credit until the company releases its new search platform and improves monetization," the firm said.
Motorola (nyse: MOT - news - people ) will report third-quarter results on Tuesday after the close of trading. The Wall Street consensus calls for the handset maker to report earnings of 34 cents per share on revenue of $11.07 billion, or respective growth of 13% and 17% from the year-ago period. Bear Stearns said last Friday it expects Motorola to announce strong results and maintained an "outperform" rating on the stock.
InterMune (nasdaq: ITMN - news - people ) shares jumped 30% in heavy after-hours trading following the biotech firm's announcement that it will team up with Swiss drug giant Roche (other-otc: RHHVF - news - people ) to develop its experimental hepatitis C treatment. The deal calls for Roche to pay InterMune $60 million upfront, with potential milestone payments of up to $470 million. In addition, Roche will foot two-thirds of the costs to develop the drug, code-named ITMN-191, which is expected to enter early-stage clinical trials by the end of the year. Deutsche Bank rated InterMune shares at "hold" with a price target of $18 on Oct. 2.
Um abraço ,
The Mechanic
Enviado: 17/10/2006 14:40